Neurocrine to acquire Soleno Therapeutics for $2.9 billion
#Neurocrine #Soleno Therapeutics #acquisition #$2.9 billion #rare disease #Prader-Willi syndrome #drug development
📌 Key Takeaways
- Neurocrine Biosciences acquires Soleno Therapeutics for $2.9 billion.
- The acquisition aims to expand Neurocrine's rare disease portfolio.
- Soleno's lead drug candidate targets Prader-Willi syndrome.
- The deal is expected to close in the second half of 2024.
🏷️ Themes
Pharmaceutical Acquisition, Rare Diseases
Entity Intersection Graph
No entity connections available yet for this article.